MarketResearchReports.com: Prostate Cancer - Pipeline Review, H2 2013, New Report Launched

Prostate Cancer - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Prostate Cancer. Prostate Cancer - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Prostate Cancer.
• A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Prostate Cancer.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 413 pages, 271 tables and 14 figures, “Prostate Cancer - Pipeline Review, H2 2013” report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Prostate Cancer Overview, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Prostate Cancer Therapeutics Development, Prostate Cancer Therapeutics - Drug Profile Updates, Prostate Cancer Therapeutics - Discontinued Products, Prostate Cancer Therapeutics - Dormant Products, Prostate Cancer - Product Development Milestones.  The report covers 185 companies; few are Bio-Path Holdings, Inc., ZIOPHARM Oncology, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Aphios Corporation, Astellas Pharma Inc., BioMarin Pharmaceutical Inc., GTx, Inc., Nippon Shinyaku Co., Ltd., Orion Corporation, Pfizer Inc., SuperGen, Inc., Anavex Life Sciences Corp., ValiRx Plc, Active Biotech AB, AEterna Zentaris Inc.

Find all Pharma & Healthcare Industry Reports under a single page at: Pharma and Healthcare Market Research Reports